Application of HER2 peptide vaccines in patients with breast cancer: a systematic review and meta-analysis

You, Zicong; Zhou, Weijun; Weng, Junyan; Feng, Haizhan; Liang, Peiqiao; Li, Yuhua; Shi, Fujun

doi:10.1186/s12935-021-02187-1

Cancer Cell International

Table 1 Clinical information table of the enrolled study

From: Application of HER2 peptide vaccines in patients with breast cancer: a systematic review and meta-analysis

	References	Phase	Sample size		Mean age	HLA		Lymph node		DTH (mm²)-case		DTH (mm²)-control		CD8⁺ T-cell (%)-case		Recurrence (%)		Overall survival (%)		DFS (%)
	References	Phase	Case	Control	Mean age	Case	Control	Case	Control	Pre	Post	Pre	Post	Pre	Post	Case	Control	Case	Control	Case	Control
GP2	^aMittendorf [12]/Tommy [10]	II	89	91	49	A2⁺	A2⁺	51N⁺	60N⁺	4.1	15.3	3.9	8	0.8	1.5	5.12	2.35	92.13	95.6	82.9	80.4
	Clifton [30]	I	17	0	47	A2⁺, A3⁺		13N⁺		28	68			46^*10⁶	144^*10⁶
	Carmichael [11]	I	18	0	47	A2⁺		18N⁻		0	27.5			0.4	1.1
GP2 Total	3 trials		124	91
E75	Clifton [7]	II	136	139	51	A2⁺, A3⁺, A24⁺, A26⁺		81N⁺	88N⁺	1.6	7.9	2	2.1	0.025	0.09	8.82	14.4			89.8	83.8
	Clifton [32]	II	81	69	52	A2⁺, A3⁺, A24⁺, A26⁺	A2⁺, A3⁺, A24⁺, A26⁺	49N⁺	44N⁺
	Mittendorf [8]	III	382	376	51.8	A2⁺, A3⁺	A2⁺, A3⁺	373N⁺	366N⁺							6.3	9.8			77.1	77.5
	Mittendorf [9]	I, II	108	79	55	A2⁺, A3⁺	A2⁻, A3⁻	53N⁺	44N⁺	1.2	13.7	0.4	1.7			10	20			89.7	80.2
	Mittendorf [33]	I, II	106	76	55	A2⁺, A3⁺	A2⁻, A3⁻	51N⁺	43N⁺							5.6	13.1			94.3	86.8
	Holmes [34]	I, II	53	0	58	A2⁺, A3⁺		27N⁺		NA	99.4			0.3	0.99
	Patil [22]	I, II	106	81	56	A2⁺, A3⁺	A2⁻, A3⁻	46N⁺	53N⁺	3	14	3.2	3.5			8.3	14.8
	Gates [35]	I	24	22	63	A2⁺	A2⁻			5	31.5	1.6	9.7			28.6	26.3	95.2	100
	Benavides [36]	II	85	66	54	A2⁺, A3⁺	A2⁻,	49N⁺	42N⁺	4	14.84	NA	1.1	0.73	1.83	11.7	18.2	98.8	92.42
	Peoples [20]	II	101	85	57	A2⁺, A3⁺	A2⁻, A3⁻	45N⁺	46N⁺	0.5	14	1.4	2.1	0.39	1.8	5.6	14.2	99	95.1	92.5	77
	Holmes [23]	II	99	0		A2⁺, A3⁺		48N⁺		2.7	21.5			0.416	1.78	10.1
	Amin [27]	II	101	85		A2⁺, A3⁺	A2⁻, A3⁻	45N⁺	46N⁺	12.8	13.625	NA	2.64	0.42	1.79	8.3	14.8	99	93.8	88	58
	Stojadinovic [37]	I	16	NA	52	A2⁺		16N⁺		NA	22.3	NA	3	0.36	0.65
	Dehqanzada [38]	I, II	36	0	59.7	A2⁺	A2⁻	12N⁺
	Dehqanzada [39]	I, II	32	0	57	A2⁺		10N⁺
	Hueman [40]	II	7	17		A2⁺	A2⁻	7N⁻	17N⁻					58.8	67.4
	Hueman [41]	I	22	22		A2⁺	A2⁻	22N⁻	22N⁻					0.75	1.2
	Mittendorf [42]	I	44	0		A2⁺	A2⁻	24N⁺						0.5	1.68
	Peoples [21]	I	24	29		A2⁺	A2⁻	24N⁺	29N⁺	NA	33	NA	7	0.56	1.66	8.3	20.7	100	93	85.7	59.8
	Murray [43]	I	13	0	48	A2⁺		6N⁺		NA	7.83
	Knutson [44]	I	4	10	48	A2⁺	A2⁺
E75 Total	21 trials		1580	1156

NA not available, DTH delayed hypersensitivity reaction, HLA human leukocyte antigen, DTH delayed-type hypersensitivity reaction, DFS disease-free survival rate, HLA-A2^± A2^± human leukocyte antigen A2 positive/negative, HLA-A3^± A3^± human leukocyte antigen A3 positive/negative , HLA-A24^± A24^± human leukocyte antigen A24 positive/negative, HLA-A26^± A26^± human leukocyte antigen A26 positive/negative
^aTommy A(2020) and Mittendorf EA(2016) ¹⁷reported the same clinical trial

Back to article page

ISSN: 1475-2867

Contact us

General enquiries: journalsubmissions@springernature.com